Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

156.35
-7.9150-4.82%
Post-market: 156.350.00000.00%19:21 EDT
Volume:680.80K
Turnover:107.84M
Market Cap:8.00B
PE:-42.49
High:163.89
Open:163.89
Low:155.56
Close:164.27
52wk High:191.50
52wk Low:86.99
Shares:51.15M
Float Shares:41.87M
Volume Ratio:1.05
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6800
EPS(LYR):-3.6821
ROE:-252.11%
ROA:-16.81%
PB:90.58
PE(LYR):-42.46

Loading ...

Axsome Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Nov 05, 2025

Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright

TIPRANKS
·
Nov 04, 2025

RBC Raises Price Target on Axsome Therapeutics to $198 From $189, Keeps Outperform Rating

MT Newswires Live
·
Nov 04, 2025

Axsome Therapeutics (AXSM) Receives a Buy from Bank of America Securities

TIPRANKS
·
Nov 04, 2025

Axsome Therapeutics Price Target Maintained With a $154.00/Share by Needham

Dow Jones
·
Nov 04, 2025

U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx, Cardinal Health

Reuters
·
Nov 04, 2025

Axsome Therapeutics Reports Strong Q3 2025 Growth

TIPRANKS
·
Nov 04, 2025

Axsome Therapeutics (AXSM): Losses Worsen 24.5% Annually, Testing Bullish Growth Narratives

Simply Wall St.
·
Nov 04, 2025

Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion

TIPRANKS
·
Nov 04, 2025

Axsome Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Nov 04, 2025

Axsome Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Nov 04, 2025

Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating

TIPRANKS
·
Nov 04, 2025

Stock Track | Axsome Therapeutics Plunges 8.39% Despite Strong Q3 Revenue as Losses Widen

Stock Track
·
Nov 03, 2025

Stock Track | Axsome Therapeutics Plunges 5.90% Pre-Market Despite Strong Q3 Revenue Growth as Losses Widen

Stock Track
·
Nov 03, 2025

Axsome Therapeutics Q3 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
Nov 03, 2025

Axsome Therapeutics Q3 Adj. EPS $(0.68) Beats $(0.87) Estimate

Benzinga
·
Nov 03, 2025

Earnings Flash (AXSM) Axsome Therapeutics Posts Q3 Net Loss $0.94 a Share, vs. FactSet Est of $0.82 Loss

MT Newswires Live
·
Nov 03, 2025

Axsome Therapeutics Q3 Sales $170.992M Beat $162.545M Estimate

Benzinga
·
Nov 03, 2025

BRIEF-Axsome Therapeutics Q3 Net Income USD -47.229 Million

Reuters
·
Nov 03, 2025

Axsome Therapeutics reports third quarter 2025 net product revenue of $171 million

Reuters
·
Nov 03, 2025